Article FDA Thank You The next chapter in the ctDNA story: Still promising, not ready for prime time
Agency IQ
JULY 21, 2023
The next chapter in the ctDNA story: Still promising, not ready for prime time A recent workshop summed up the state of play for circulating tumor DNA. It’s not necessarily just the assays themselves that need to be standardized, but when and how they are being used by clinicians.
40 
Let's personalize your content